DexCom Inc (DC4.HA)
| Previous close | 115.80 |
| Open | 116.70 |
| Bid | 116.20 x N/A |
| Ask | 117.06 x N/A |
| Day's range | 116.70 - 116.70 |
| 52-week range | 71.37 - 130.20 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 25 July 2024 - 29 July 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
ZacksWhy DexCom (DXCM) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Simply Wall St.With EPS Growth And More, DexCom (NASDAQ:DXCM) Makes An Interesting Case
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...
Business WireDexcom Launches Innovative New Sensor as Groundbreaking Report Reveals Alarming Rates of Anxiety and Depression in Those With Type 2 Diabetes
LONDON, May 20, 2024--DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today announced both the launch of Dexcom ONE+, a CGM device that easily tracks real-time glucose readings to help improve diabetes management, and the Dexcom State of Type 2 Report. The report is a first-of-its-kind look at the Type 2 landscape today and examines the preferences and behaviours of those living with the condition, as well as their caretaker
